Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

被引：0

作者：

Di Giacomo, A. M. ^{[1
]}

Simonetti, E. ^{[2
]}

Calabro, L. ^{[3
]}

Vegni, V. ^{[4
]}

Santangelo, F. ^{[5
]}

Depenni, R. ^{[6
]}

Colucci, M. ^{[2
]}

Valente, M. ^{[5
]}

Grifoni, R. ^{[7
]}

Lofiego, M. F. ^{[2
]}

Amato, G. ^{[5
]}

Keer, H. N. ^{[8
]}

Oganesian, A. ^{[8
]}

Chan, D. ^{[8
]}

Giannarelli, D. ^{[9
]}

Altomonte, M. ^{[5
]}

Ceccarelli, M. ^{[10
,11
]}

Anichini, A. ^{[12
]}

Covre, A. ^{[2
]}

Maio, M. ^{[1
]}

机构：

[1] Univ Siena, Univ Hosp Siena, NIBIT Fdn Onlus, Ctr Immunooncol,Oncol, Siena, Italy

[2] Univ Siena, Med Oncol, Siena, Italy

[3] Univ Ferrara, Med Oncol, Ferrara, Italy

[4] NIBIT Fdn Onlus, Radiol, Siena, Italy

[5] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy

[6] Univ Modena, Med Oncol, Modena, Italy

[7] Azienda USL Toscana Centro, Med Oncol, Florence, Italy

[8] Taiho Pharmaceut Inc, Clin Dev, Pleasanton, CA USA

[9] Fdn Policlin Gemelli, Biostat, Rome, Italy

[10] Univ Miami, Miller Sch Med, Computat Biol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL USA

[12] Fdn IRCCS Ist Nazl Tumori, Expt Oncol, Human Tumors Immunobiol Unit, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA47

引用

页码：1237 / 1237

页数：1

共 50 条

[31] Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab
Weber, Jeffrey S.
Kudchadkar, Ragini Reiney
Gibney, Geoffrey Thomas
De Conti, Ronald C.
Yu, Bin
Wang, Wenshi
Sarnaik, Amod
Martinez, Alberto J.
Kroeger, Jodi
Eysmans, Cabell
Gallenstein, Donna
Zhao, Xiuhua
Chen, Ann
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
T. M. L. Tong
M. K. van der Kooij
F. M. Speetjens
A. R. van Erkel
R. W. van der Meer
J. Lutjeboer
E. L. van Persijn van Meerten
C. H. Martini
R. W. M. Zoethout
F. G. J. Tijl
C. U. Blank
M. C. Burgmans
E. Kapiteijn
Trials, 23
[33] Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
Juloori, Aditya
Katipally, Rohan R.
Lemons, Jeffrey M.
Singh, Anurag K.
Iyer, Renuka
Robbins, Jared R.
George, Ben
Hall, William A.
Pitroda, Sean P.
Arif, Fauzia
Fung, John
Pillai, Anjana
Liao, Chih-Yi
Sharma, Manish
Liauw, Stanley L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (01): : 202 - 213
[34] Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
Tong, Thais M. L.
Burgmans, Mark C.
Van der Kooij, Monique
Speetjens, Frank M.
van Erkel, Arian R.
van der Meer, Rutger W.
van den Bosch, Shelley
Jonker, Mare A.
Roozen, Inge C. F. M.
Lutjeboer, Jacob
Rijksen, Fenna
van Persijn-van Meerten, Els L.
Martini, Chris H.
Zoethout, Remco W. M.
Tijl, Fred G. J.
Blank, Christian U.
Kapiteijn, Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
Tong, T. M. L.
van der Kooij, M. K.
Speetjens, F. M.
van Erkel, A. R.
van der Meer, R. W.
Lutjeboer, J.
van Meerten, E. L. van Persijn
Martini, C. H.
Zoethout, R. W. M.
Tijl, F. G. J.
Blank, C. U.
Burgmans, M. C.
Kapiteijn, E.
TRIALS, 2022, 23 (01)
[36] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[37] Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Cao, Hop Sanderson Tran
Mohamed, Yehia, I
Qayyum, Aliya
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Lee, Sunyoung S.
Raghav, Kanwal Pratap Singh
Altameemi, Lina
Rashid, Asif
Vauthey, Jean-Nicolas
Carter, Kristen
Tzeng, Ching-Wei David
Chun, Yun Shin
Yao, James C.
Wolff, Robert A.
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] 1 Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Zamarin, Dmitriy
Burger, Robert A.
Sill, Michael W.
Powell, Daniel J., Jr.
Lankes, Heather A.
Feldman, Michael D.
Zivanovic, Oliver
Gunderson, Camille
Ko, Emily
Mathews, Cara
Sharma, Sudarshan
Hagemann, Andrea R.
Khleif, Samir
Aghajanian, Carol
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1814 - +
[39] A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
Di Giacomo, A. M.
Ascierto, P. A.
Pittiglio, E.
Queirolo, P.
Pilla, L.
Ridolfi, R.
Santinami, M.
Testori, A.
Parmiani, G.
Maio, M.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S653 - S654
[40] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
Kaseb, Ahmed Omar
Pestana, Roberto Carmagnani
Vence, Luis M.
Blando, Jorge M.
Singh, Shalini
Ikoma, Naruhiko
Vauthey, Jean-Nicolas
Allison, James Patrick
Sharma, Padmanee
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →